State of New Jersey Common Pension Fund D Boosts Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

State of New Jersey Common Pension Fund D lifted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.7% during the 3rd quarter, Holdings Channel reports. The fund owned 473,509 shares of the company’s stock after buying an additional 16,700 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Teva Pharmaceutical Industries were worth $8,533,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Atria Investments Inc raised its holdings in Teva Pharmaceutical Industries by 135.4% in the 3rd quarter. Atria Investments Inc now owns 30,856 shares of the company’s stock valued at $556,000 after buying an additional 17,746 shares during the period. Greenwood Capital Associates LLC purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $4,267,000. Catalyst Capital Advisors LLC purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $2,019,000. National Pension Service raised its holdings in Teva Pharmaceutical Industries by 107.3% in the 3rd quarter. National Pension Service now owns 3,170,640 shares of the company’s stock valued at $57,135,000 after buying an additional 1,640,940 shares during the period. Finally, Robeco Institutional Asset Management B.V. grew its position in Teva Pharmaceutical Industries by 73.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 465,032 shares of the company’s stock valued at $8,380,000 after acquiring an additional 197,585 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 2.2 %

Shares of TEVA stock opened at $17.11 on Monday. The business’s fifty day moving average price is $17.94 and its 200 day moving average price is $17.15. Teva Pharmaceutical Industries Limited has a 1-year low of $8.55 and a 1-year high of $19.31. The firm has a market capitalization of $19.38 billion, a PE ratio of -20.13, a P/E/G ratio of 1.33 and a beta of 0.87. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.59.

Analysts Set New Price Targets

Several research firms have weighed in on TEVA. Barclays lifted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. UBS Group boosted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.